mobile header
Dr Moulish Reddy

Dr Moulish Reddy american Oncology Hospitals

Dr Moulish Reddy

Nuclear Medicine

Book an Appointment
Share Profile share

Dr Moulish Reddy is experienced specialist in the field of Nuclear Medicine, with a strong focus on advanced diagnostic imaging and radionuclide therapies. With extensive clinical expertise in PET-CT, SPECT-CT, and targeted molecular imaging, committed to providing precise, personalized care for a wide range of conditions, including cancer, cardiac diseases, and thyroid disorders. After completing his specialized training in Nuclear Medicine from reputed institutions like AIIMS Raipur,he has been actively involved in clinical practices, researches, and academic teaching. His clinical interests include oncologic imaging for early cancer detection, staging and radioiodine therapy for thyroid disorders.

He has independently reported FDG, PSMA, DOPA PET-CT for both oncological and non-oncological applications. He is specialized in the intricate interpretation of more than 1500 PET-CT scans while gaining expertise in diagnosing diverse medical conditions with high precision and accuracy. Dr Reddy is Proficient in gamma camera imaging, including cardiovascular imaging, renal dynamic scintigraphy, skeletal scintigraphy, thyroid imaging, renal cortical imaging (DMSA), hepatobiliary scintigraphy, and ventilation-perfusion imaging. He has performed FDG PET-CT-guided biopsies on lung lesions independently, utilizing the MAXIO guidance system and assisted more than 50 PET guided biopsies.

He is also experienced in the field of radionuclide therapy, including low- dose I-131 therapy, for individuals with Grave's disease and differentiated thyroid carcinoma with regular clinical follow up.

  • MD (Nuclear Medicine) - All India Institute of Medical Sciences (AIIMS), Raipur - 2022-2025
  • MBBS - Andhra Medical College, Vizag - 2014-2019
  • Junior Resident - AIIMS, Raipur (January 2022 to January 2025)
  • Intern - King George Hospital, Andhra Medical College, Visakhapatnam (March 2019 to March 2020)
  • PET-CT Imaging: 18-F FDG PET-CT, 18-F PSMA PET-CT, 18-F DOPA PET-CT
  • PET-CT Guided Metabolic Biopsy: Robotic Arm Guided Biopsy, Especially for Lung Masses
  • Radionuclide Therapy: Low Dose I-131 Therapy for Metastatic DTC/Grave’s Disease
  • Evaluation of Dementia and Movement Disorders - Autoimmune Encephalitis studies using PET-CT
  • Radionuclide Therapy Techniques
  • Conventional Nuclear Medicine: Cardiovascular Imaging, Thyroid Imaging, Renal Dynamic Imaging, Bone scan, Lymphoscintigraphy
  • Reddy Moulish, Ravina M, Goyal H, Kumar A, Kote R. Nivolumab and Cabozantinib Immunotherapy Induced Thyroid Dysfunction Detected on 18F-FDG PET/CT in Renal Cell Carcinoma. Clin Nucl Med. 2024 Oct;49(10):e523
  • Mishra, Ajit; Ravina, Mudalsha; Kote, Rutuja; Kumar, Amit; Kashyap, Yashwant; Dasgupta, Subhajit; Reddy, Moulish.Role of textural analysis parameters derived from FDG PET/CT in differentiating hepatocellular carcinoma and hepatic metastases. Nuclear Medicine Communications 44(5):p 381- 389, May 2023.
  • Mishra, Ajit*; Ravina, Mudalsha1,*; Kote, Rutuja1; Kumar, Amit2; Kashyap, Yashwant2; Dasgupta, Subhajit1; Reddy, Moulish1. Role of Textural Analysis of Pretreatment 18F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Prediction in Esophageal Carcinoma Patients. Indian Journal of Nuclear Medicine 38(3):p 255-263, Jul–Sep 2023. 
  • A compilation of Orbital and Ocular Adnexal Lymphomas on 18F-FDG PET/CT Imaging- Accepted for publication in Clinical Nuclear Medicine. Reddy Moulish*, Ravina M*, Kumar A, Kote R, Vijaya
  • Paper Presentation: Correlation of myocardial perfusion imaging with coronary artery calcification scoring in evaluation of coronary artery disease in an intermediate risk population to alter treatment strategy, ANMPICON 2023, September 2023.
  • Third Prize for Paper Presentation in NCSICON 2023, Correlation of myocardial perfusion imaging with coronary artery calcification scoring in evaluation of coronary artery disease in an intermediate risk population to alter treatment strategy.
  • APMC/FMR/110597

Recommended Doctors